Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952097 | PMC |
| http://dx.doi.org/10.3389/fneur.2024.1377129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Advances in non-invasive brain stimulation techniques.
Front Neurosci
December 2024
Department of Information Science, University of North Texas, Denton, TX, United States.
Influence of early-life stress on hippocampal synaptic and network properties.
Front Neural Circuits
January 2025
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
According to the World Health Organization, the number of people suffering from depressive disorders worldwide is approaching 350 million. The consequences of depressive disorders include considerable worsening of the quality of life, which frequently leads to social isolation. One of the key factors which may cause depression in adulthood is early life stress, in particular, insufficient maternal care during infancy.
View Article and Find Full Text PDFTrace amine-associated receptor 1 agonist reduces aggression in brain serotonin-deficient tryptophan hydroxylase 2 knockout rats.
Front Psychiatry
December 2024
Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.
Introduction: Aggression and self-harm disproportionately occur in youths preoccupied with social status tracking. These pathological conditions are linked to a serotonin (5-HT) deficit in the brain. Ablation of 5-HT biosynthesis by tryptophan hydroxylase 2 knockout (TPH2-KO) increases aggression in rodents.
View Article and Find Full Text PDFMDMA and MDMA-Assisted Therapy.
Am J Psychiatry
January 2025
Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School (Fonzo, Nemeroff); Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, UCLA (Grzenda); Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (Kraguljac); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, Stanford University and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).
Article Synopsis
- MDMA, also known as Ecstasy or Molly, has been used since the 1970s for both recreational and therapeutic purposes, with the FDA recognizing its potential for treating PTSD as a Breakthrough Therapy in 2017.
- The effects of MDMA in therapeutic settings are distinct, promoting trust and self-compassion while allowing cognitive clarity, which differentiates it from other psychedelics.
- Preliminary evidence indicates that MDMA-Assisted Therapy is effective, with 67%-71% of PTSD patients no longer meeting diagnostic criteria after treatment, significantly more than those receiving placebo therapy.
Psilocybin: From Psychiatric Pariah to Perceived Panacea.
Am J Psychiatry
January 2025
Department of Psychiatry and Behavioral Sciences (Fonzo, Barksdale, Nemeroff) and Center for Psychedelic Research and Therapy (Fonzo, Nemeroff), University of Texas at Austin Dell Medical School, Austin; Institute for Early Life Adversity Research, University of Texas at Austin, Austin (Fonzo, Nemeroff); Department of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD (Wolfgang); Department of Psychiatry, Yale University School of Medicine, New Haven, CT (Wolfgang, Krystal); Butler Hospital, Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI (Carpenter); Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham (Kraguljac); Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles (Grzenda); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA (Rodriguez); Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).
Objective: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors.
Methods: PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were identified and screened through titles and abstracts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!